⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

October 2, 2024

Supplementary Figure 5 from NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD⁺ Depletion

View Full Paper

Ask AI

Bookmark

Share

Abstract

Relationships between NAPRT, NAMPT, PARP, and QPRT expression in cancer cell lines.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Noronha et al. (2024) studied this question.

synapsesocial.com/papers/68e56004e2b3180350efd14d https://doi.org/10.1158/1541-7786.27151075

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure 6 from NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD<sup>+</sup> Depletion2024
2Supplementary Figure 2 from NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD<sup>+</sup> Depletion2024
3Supplementary Figure 4 from NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD<sup>+</sup> Depletion2024
4Supplementary Figure 3 from NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD<sup>+</sup> Depletion2024
5Supplementary Figure 8 from NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD<sup>+</sup> Depletion2024